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Abstract 
We review diagnostic and predictive roles of the angiogenic proteins placental growth factor, 
soluble fms-like tyrosine kinase 1 and soluble endoglin in preeclampsia, and their association with 
future cardiovascular disease, diabetes and breast cancer. Specific patterns of these proteins 
represent preeclamptic prediction markers and combined with maternal and clinical characteristics, 
the predictive values increase. Women experiencing preeclampsia have increased risks of 
developing cardiovascular diseases and diabetes, and a decreased risk of breast cancer. High 
placental growth factor concentrations have in elderly patients been shown to predict cardiovascular 
events. Diabetes is also a risk factor for future cardiovascular disease. Diabetic vascular 
complications are associated with increased soluble endoglin concentrations, and vascular 
endothelial growth factor concentrations are correlated to HbA1c and fasting glucose. Thus 
dysregulation in angiogenic proteins may link preeclampsia and cardiovascular diseases, targeting 
women who could in future benefit from prophylactic programs topossibly prevent, delay or reduce 
cardiovascular disease.  
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Key Message: 
 
 
 
Dysregulated circulating angiogenic proteins are associated with preeclampsia and placental 
dysfunction. These proteins may also be dysregulated in diabetes, cardiovascular disease and 
breast cancer. We suggest potential  pathophysiological links, and through these some 
possibilities for prevention directed towards young women at increased risk for these 
diseases. 
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Abbreviations: 
FGR: fetal growth restriction 
CVD: cardiovascular disease 
DM: diabetes mellitus 
SGA: small-for-gestational age 
GDM: gestational diabetes 
PlGF: placental growth factor 
sFlt1: soluble fms-like tyrosine kinase-1 
sEng: soluble endoglin 
VEGF: vascular endothelial growth factor  
 
Introduction  
 
Preeclampsia and fetal growth restriction (FGR) are pregnancy complications associated 
with an increased risk for short- and long-term morbidity and mortality for both the mother and her 
offspring, such as adding to the risk for developing future cardiovascular disease (CVD) and 
diabetes mellitus (DM) (1;2). Simultaneously, women have a decreased risk of breast cancer 
development after preeclampsia (3-5), although this is not confirmed in all epidemiological studies 
(6). 
The patophysiology of the preeclampsia syndrome is still elusive and not completely 
understood. The disease is, however, clinically and pragmatically usually defined as hypertension 
and proteinuria developing after 20 weeks of gestation (7). Preeclampsia has often been subdivided 
into “placental” and “maternal” forms, stating unique patterns of pathogenesis and health issues 
both in the short and long term (8;9).  
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“Placental preeclampsia” is thought to arise from incomplete remodeling of the 
uteroplacental spiral arteries, presumably caused by dysregulated immunological interactions 
between fetal extravillous trophoblasts and maternal immune cells (10) leading to dysfunctional 
uteroplacental flow and excessive oxidative and endoplasmatic reticulum stress in the placenta (11). 
The dysfunctional placenta releases factors into the circulation causing a systemic inflammatory 
response (12) and generalized endothelial dysfunction mediating the clinical maternal signs of 
hypertension and proteinuria (13). These placenta-generated factors include angiogenic proteins, 
and we have previously discussed their application in pregnancy as biomarkers of a dysfunctional 
placenta (14). 
“Maternal preeclampsia” is considered to develop in women with a normal placentation.  
Predisposing factors associated with augmented inflammation such as obesity, DM and 
autoimmune diseases make the mother more susceptible to developing endothelial dysfunction, 
hypertension and proteinuria as a response to factors released from a normally functioning placenta 
(1). “Placental preeclampsia”, with incompletely remodeled uteroplacental spiral arteries, is  thought 
to more often associated with early-onset disease and FGR, whereas the “maternal type” of 
preeclampsia, without apparent remodeling problems, is more often associated with late-onset 
disease, although a mix of both these not well-defined preeclampsia forms is probably the more 
common condition (14).  
The risk factors for developing preeclampsia seem also to segregate into the two subgroups 
of preeclampsia. Previous preeclampsia and nulliparity deviate towards the “placental” type, 
whereas obesity, high maternal age and diabetes, – much the same risk factors as for CVD,  – 
predispose to the “maternal type” (15). These clinical factors have, however, a limited predictive 
value in evaluating the risk for preeclampsia (16). Likewise, pathological blood flow patterns in the 
uterine artery assessed by Doppler ultrasound, have limited value in the general screening for low-
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risk pregnancies. Uterine artery blood flow as well as umbilical cord flow patterns are, however, 
widely used in the clinical setting to follow up high-risk patients with present or previous pregnancy 
complications associated with placental dysfunction (16). 
No cause-specific treatment for clinically established preeclampsia is available at present. 
Delivery of the baby and thereby the placenta leads to amelioration of the clinical symptoms, 
paralleling a rapid decrease in the maternal circulating level of anti-angiogenic factors. Following a 
preeclamptic pregnancy, both the woman and her offspring are, however, at elevated risk for 
developing CVD (2;17-22). The American Heart Association introduced in 2011 preeclampsia and 
FGR as risk factors for CVD (23), but there is today no agreed follow-up protocol for CVD relating 
to pregnancy complications, partly due to an inability to identify the women at highest risk within 
these populations.  
An improved subclassification of preeclampsia and FGR based on unique patterns of 
angiogenic biomarkers rather than on crude syndromic signs may provide useful in triaging women 
for follow-up, both during pregnancy and postpartum (14). This might prove valuable for better 
timing of delivery in a pregnancy at risk for adverse maternal and offspring outcomes, and could be 
followed by potentially improved health outcomes for the mother and offspring (14).  
Several distinct circulating maternal angiogenic proteins appear to be present at abnormal 
levels in pregnant women with overt preeclampsia or growth restricted fetuses; furthermore, the 
relative and absolute concentrations of these proteins are altered prior to the clinical signs of these 
pregnancy complications (16;24). This review summarizes the findings for the most assessed anti- 
and pro-angiogenic circulating proteins in relation to pregnancy complications and their potential 
predictive roles hereto. In addition, a potential role of these circulating biomarkers in relation to 
future adult CVD, DM and breast cancer is discussed. 
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Material and methods 
 
For the present review, a non-systematic PubMed search on was performed. Search words 
included “Preeclampsia/Intrauterine Growth Restriction/FGR/Small-for-Gestational 
Age/CVD/DM/Breast Cancer” in a combination with “Angiogenic 
factors/PlGF/sFlt/sEng/Prediction”. Additional eligible studies were sought by hand search of 
reference lists from primary articles and reviews. We published a comprehensive review of 
potential preeclamptic plasma biomarkers in 2010 (16), with a completed article search up to 
September 2009.  
The present review has in addition included published articles as a result of a second 
PubMed search from September 2009 to November 2012, using same search words as above, 
primarily clinical cohort studies, case-control studies and clinical trials. We selected relevant 
published articles in English, based upon the senior authors’ expertise of the field (A.C.S. and 
J.A.L.). This review is based on a report in 2013 by the first author, and important published articles 
on the topic from 2013 and 2014 were thereafter included under the same criteria as above. This 
review does not present a graded evaluation of the statistically significant associations presented 
between the angiogenic biomarkers and disease.  
 
Results 
 
Preeclampsia and future health risks 
Several studies have shown increased risk of long-term cardiovascular complications such as 
coronary heart disease, tromboembolism, hypertension, stroke and CVD-associated death following 
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a history of preeclampsia or the delivery of a small-for-gestational age (SGA) infant (10;17-19;25-
31). The risk is highest among women who develop both preeclampsia and FGR (28), for those 
with early-onset preeclampsia (17;18;25;31), repeated preeclampsia (28) or severe preeclampsia 
(18). The relative risk after preeclampsia for developing CVD varies from 1.3 to 3.3, with a higher 
risk range of 2.7-8.1 in more severe preeclampsia (32), implying a “dose-response” relation 
between severity of preeclampsia and future CVD. FGR implies failure to realize a genetically 
determined growth potential and many FGR fetuses, but not all, will also be SGA.  Not all SGA 
fetuses are FGR, they are just constitutionally small. The fetal growth terminology is controversial 
and inconsistent among obstetricians; however, the most widely used definition of SGA is fetal 
weight below the 10
th
 percentile (33). 
 Cardiovascular risk factors present before a hypertensive pregnancy could be important 
determinants of subsequent long-term cardiovascular risk after a preeclamptic pregnancy, but this 
does not exclude that the pregnancy by itself, and a pregnancy complication with poor placental 
function like the “placental” type of preeclampsia in particular (8;9), could also contribute to the 
augmented risk for later cardiovascular disease.  
DM and preeclampsia share many pathophysiological features, such as inflammation, 
oxidative stress, insulin resistance and endothelial dysfunction (34;35). Both pre-gestational and 
gestational diabetes (GDM) are associated with an increased risk of developing preeclampsia (36-
38). ). Lykke et al. have demonstrated that a history of preeclampsia or gestational hypertension 
(39), as well as of FGR (40), places women at increased risk of DM later in life, in line with 
previous publications demonstrating increased risk of type II DM after preeclampsia (41), even in 
patients without co-existing GDM (42). Insulin resistance is a feature of normal pregnancy which is 
exaggerated in preeclampsia and even more so in GDM, and it may represent a link between these 
pregnancy complications and future DM and CVD (43;44).  
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In contrast to an augmented risk of diseases such as CVD and DM following preeclampsia, 
women with a history of preeclampsia or gestational hypertension have a reduced breast cancer risk 
compared to women who have had only uncomplicated pregnancies (45;46). An even larger 
reduction is seen with elevated mean arterial pressures (47) and systolic blood pressures from mid- 
to late pregnancy, but below the diagnostic levels for preeclampsia (48). This inverse correlation 
between breast cancer and a history of preeclampsia is, however, not consistent (49). The 
mechanisms are at present unknown, but might be related to tumor vascularization and growth, and 
possibly to remote effects of dysregulated local or circulating angiogenic factors during pregnancy. 
 
 
Angiogenic factors and preeclampsia  
Preeclampsia is characterized by a maternal circulating anti-angiogenic profile, with 
elevated anti-angiogenic proteins, and decreased pro-angiogenic proteins (reviewed in (16)). This 
pattern is also seen prior to clinical signs of preeclampsia, and in animal models, these proteins 
participate in processes that induce preeclampsia-like disorders (50-53). 
In normal pregnancies, the pro-angiogenic protein placental growth factor (PlGF) peaks at 
30 weeks (54) and decreases towards term (55;56). It is involved in angiogenesis and 
vasculogenesis, which are important processes in embryogenesis (57) and placentation. In 
preeclampsia, circulating PlGF is decreased (58-62), especially in cases of early-onset preeclampsia 
(59;60;62), although there are some discrepant findings (61). When it comes to predicting 
preeclampsia, some studies have demonstrated that low concentrations of PlGF predict the disease 
already from late first trimester (16;63-70). Other studies did not find any predictive value early in 
pregnancy (16;56;59;71), or only for early-onset preeclampsia (64). The predictive power of a low 
maternal PlGF blood concentration seems in general poorer for predicting late- than early- onset 
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preeclampsia, and performs less well for  preeclampsia without SGA compared to preeclampsia 
complicated by SGA (66). 
Most studies have demonstrated low PlGF as a preeclampsia predictor from the second 
trimester onwards (16;56;63;67;72-77), especially if preeclampsia was complicated by SGA 
(56;60;71;72), as well as in early-onset (56;67) and severe preeclampsia (59;65). The same has been 
seen for the third trimester (74-76), especially (and in some studies exclusively (59)) in severe 
preeclampsia (78). Other studies have demonstrated that a low increase in PlGF from the first to 
second trimester gives a stronger association to an augmented  risk than low PlGF levels, again 
especially for the prediction of early-onset preeclampsia (67;69;72). A recently published study has 
shown that in women presenting with suspected preeclampsia before 35 weeks' gestation, low PlGF 
had a higher sensitivity and negative predictive value for preeclampsia within 14 days (79).  
As opposed to PlGF, the maternal concentrations of the “anti-angiogenic protein” soluble 
fms-like tyrosine kinase-1 (sFlt1) remain stable during the first two trimesters of a normal 
pregnancy, and thereafter increase towards term (56;80). The action of sFlt1 and its interaction with 
the “pro-angiogenic proteins” vascular endothelial growth factor (VEGF) and PlGF during 
pregnancy is complex (14). It is believed that sFlt1 acts as a “decoy protein” in pregnancy, reducing 
free concentrations of VEGF and PlGF, thereby reducing the vasodilation effect on the 
endothelium, thus at the same time inducing vasoconstriction and contributing to the development 
of hypertension and proteinuria (58). An increased concentration of sFlt1 in the maternal circulation 
has been shown in preeclamptic patients (9), both in second and third trimester (52;60-62;81-84). 
The associations are, similarly as for PlGF, stronger in early-onset (60;61;81) and severe 
preeclampsia (52), however, not all studies agree hereto (62;85). Elevated sFlt1 concentrations in 
pregnancy have also been associated with smaller head and chest circumferences and with 
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birthweight  (86), as well as being positively correlated to mean arterial pressure and proteinuria 
(58;84), although there are some discrepant conclusions (62). 
As for predicting preeclampsia, low sFlt1 concentrations in the first trimester appear to 
predict early-onset preeclampsia in some studies (67;72), and a high sFlt1 increase from the first to 
the second trimester may entail an augmented risk of preeclampsia (72). Results from the latter 
cohort recently showed that low sFlt1 in the first trimester could predict early-onset preeclampsia 
independently of SGA, and also late-onset preeclampsia together with SGA (69). Other studies have 
not shown a predictive value for sFlt1in the first trimester (56;67;68;87). 
For the second and third trimester, most studies show that elevated maternal sFt1 
concentrations predict preeclampsia development (16;56;59;62;64;69;73-76;87;88), with a higher 
predictive power for early- than for late-onset preeclampsia (16;56;88), however, some studies have 
concluded otherwise (16;63;67). Furthermore, elevated sFlt1 has been suggested to be a better 
predictor of severe preeclampsia (78;88), or preeclampsia complicated by SGA (56). A study by 
Powers et al. suggested a dichotomized preeclampsia population. One subpopulation had elevated 
maternal sFlt before gestational week 35, representing the preeclampsia group with the highest 
blood pressures, the earliest gestational age at delivery and the most preterm births (59). This was in 
comparison to the second group of preeclamptic patients with an sFlt1 increase not seen until after 
week 35, lower blood pressures, less preterm deliveries and the highest gestational age at delivery.  
It seems that for late-onset preeclampsia, a significant increase in maternal circulating sFlt1 is only 
present close to the time of the diagnosis of the disease (16;56). The preeclampsia prediction 
generally improves if SGA is diagnosed in combination with preeclampsia (69).  
Using several biomarkers simultaneously seems to improve preeclampsia subgrouping, both 
in a predictive fashion and as markers of a correct clinical diagnosis. An elevated sFlt1/PlGF ratio 
in pregnancy improved the prognostic value for preeclampsia as compared to single marker, 
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(16;60;89), correlating to adverse pregnancy outcomes (90), especially early-onset preeclampsia 
(91).  As regards existing preeclampsia, the sFlt1/PlGF ratio is also elevated (16;61;84), especially 
in the second trimester, i.e. for women with early-onset preeclampsia. Studies of the relation 
between these biomarkers in preeclampsia have suggested that the reduction in circulating maternal 
PlGF concentration can be detected prior to the sFlt1elevations, favoring PlGF as an early 
predictive marker of preeclampsia (92). Other studies conclude that PlGF is a more sensitive and 
precise predictor of preeclampsia and FGR than any other biomarker investigated previously (93-
95). 
Another maternal circulating “anti-angiogenic protein”, soluble endoglin (sEng), has also 
been demonstrated to be elevated in clinically established preeclampsia (16;51;61;62;81-84;96). It 
increases with severity of the disease (51;62), being highest in early-onset in disease (61;62). 
Endoglin (Eng) is a glycoprotein expressed on endothelial cells and on placental 
syncytiotrophoblasts, involved in transcriptional responses in the vasculature. Its soluble form, 
sEng, is proposed to act in concert with sFlt1 in pregnancy (89). Its circulating concentrations 
increase by two- and three-fold through a normal pregnancy, with regard to respectively preterm 
and term measurements, as compared to non-pregnant states (51). The predictive value of elevated 
sEng in the first trimester has, however,  not been shown to be a consistent finding. Most studies 
have not shown a predictive value for preeclampsia (67;68;87). Some studies including women late 
in first or early in second trimester (63;97), have suggested that sEng is elevated in women destined 
to develop preeclampsia, especially early-onset (97). In the second trimester the findings coincide 
better, and increased sEng seems to predict preeclampsia (74;78;98), especially the early-onset and 
severe forms, similarly to the low PlGF and elevated sFlt1 values (16;63;67;74;76;87-89;98). From 
several studies it has been suggested that a combination of maternal circulating biomarkers and 
clinical signs may improve the predictive values for preeclampsia compared to biomarkers alone 
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(16;78). A superior model is presented to be the combination of mean arterial pressure with 
circulating sEng-values, with the highest prediction for early-onset preeclampsia (99). Similar 
results have been found by combining circulating sEng with maternal factors such as race, smoking, 
parity, weight, age, and with biophysical factors such as mean arterial pressure (100). Another study 
including PlGF has shown that a combination of clinical data, maternal PlGF and β –hCG 
concentrations measured in the first trimester can predict up to 75% of early-onset preeclamptic 
cases (101), although the combination with uterine artery Doppler and maternal PAPP-A 
concentrations increased the detection to 95%, with a false positive rate of 10%, suggesting another 
possible model in the screening for early-onset preeclampsia (102).  
 
 
Angiogenic factors in relation to small-for-gestational age and fetal growth restriction 
FGR has also been associated with a dysregulated maternal angiogenic profile (16). It has 
been shown that circulating maternal PlGF is decreased in pregnancies complicated by SGA (71) or 
FGR (103), also in non-preeclamptic patients. Not all studies have found significant low PLGF 
concentrations in FGR, even with co-existing preeclampsia (60). Similarly, increased maternal sFlt1 
(62) and sEng concentrations have been found in pregnancies complicated by SGA (62;81). Not all 
studies have shown significant low PlGF concentrations in FGR, even with co-existing 
preeclampsia (60), but pregnancy biomarker studies are in general difficult to compare, as they 
differ widely in study design (particularly in gestational age inclusion for blood sampling) and 
population selection. 
As for preeclampsia, low maternal PlGF concentrations in the first trimester (16;66;67;104) 
and elevated maternal sEng in the second trimester (67;70;104) have been shown to predict SGA 
pregnancies. Maternal sFlt1 concentrations appear to be increased in non-preeclamptic pregnancies 
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later complicated by FGR (16;105;106), and recent studies have demonstrated a high sFlt1 increase 
from the first to the second trimester for predicting SGA development both in preeclamptic and 
non-preeclamptic patients (69;104). These findings are discrepant, as some studies show no 
predictive value for SGA following an elevated sFlt1 (76), and even a lower risk of SGA 
development (16;107).  
 
Angiogenic factors in relation to cardiovascular disease 
 It has been  proposed that women with acute atherosis of the uteroplacental spiral 
arteries, a feature of many pregnancies complicated by preeclampsia, could be at excessive risk for 
premature atherosclerosis and CVD development (10).  These acute atherosis lesions are 
histological changes resembling early stages of histological atherosclerosis (108), and we have 
suggested that these lesions could represent an accelerated form of early atherosclerosis developed 
during the short time of pregnancy (1).  
Another similarity between atherosclerosis and acute atherosis is the inflammatory 
component (108). PlGF is shown to be up-regulated in atherosclerotic lesions of patients with acute 
coronary syndrome, where it is believed to act as an inflammatory instigator of atherosclerotic 
plaque instability (109), and elevated circulating PlGF could indicate a risk for higher mortality and 
disease events in patients with coronary heart disease. Also, in these elderly individuals, circulating 
PlGF levels were positively correlated with levels of the inflammation marker CRP (109;110). It is 
suggested that the source of the elevated PlGF in the circulation of these patients is the inflamed 
endothelium. There is in contrast a low circulating concentration of PlGF during and prior to 
preeclampsia development, probably secondary to placental dysfunction and the binding of free and 
vascular-active PlGF as well as VEGF by the elevated amount of placenta-freed sFlt1 (52). 
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Angiogenic factors in relation to diabetes mellitus 
Angiogenic factors have also been investigated in order to improve the understanding of the 
pathogenesis and vascular complications in DM. It has been shown that elevated circulating sEng is 
correlated to microangiopathy, hypertension, increased disease duration, besides a family history of 
diabetes type 2 (111). Circulating VEGF is positively correlated to Hba1c and fasting glucose (112). 
It is important to underline that the latter pattern is the opposite of what is observed in preeclampsia, 
where it is plausible that the effect of placenta dysfunction overrides the vascular dysfunction for 
the circulating biomarkers that are measured in pregnancy. The common denominator is the 
inflamed endothelium, which in the case of preeclampsia is secondary to the placenta-mediated 
generalized (and vascular) inflammation (12). The complex patterns of pathogenesis in the two 
situations could then determine the outcome for the woman. 
 
Angiogenic factors and cancer 
The mechanisms mediating breast cancer protection after a case of gestational hypertension 
are unknown. We have speculated that the anti-angiogenic state implying negative growth 
conditions for tumor growth and metastasis plays a role in the association between a dysfunctional 
placenta and future reduced malignant tumor development (113).  The circulating anti-angiogenic 
sFlt/VEGF ratio in a woman with breast cancer is inversely associated with tumor size, and it is 
significantly lower in breast cancer patients than controls (114). Augmented concentrations of 
circulating PlGF in a woman with breast cancer have been suggested to be a positive predictor of 
breast cancer recurrence, metastasis and patient mortality, and to be associated with its angiogenic 
properties (115). However, there is currently no documentation of any relation between 
dysregulated angiogenic responses during pregnancy and later breast cancer development, although 
a possible correlation cannot be excluded. 
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Discussion 
 
The circulating maternal concentrations of the angiogenic biomarkers in pregnancy are a net 
result of many complex processes (1). The study of their association to preeclampsia, 
cardiovascular disease, diabetes mellitus and breast cancer may generate new insights to the 
pathophysiology of these diseases and suggest mechanisms for their pathophysiological interaction.  
A high release of anti-angiogenic factors such as sFlt1 from a dysfunctional placenta is proposed to 
have a negative impact on the maternal endothelium by neutralizing beneficial VEGF and PlGF in 
the circulation (52), but the direct relation of this to future vascular disease is unknown. Due to their 
relation to preeclampsia, and also to the epidemiological association between preeclampsia, DM 
and CVD, we speculate that these biomarkers may be useful in risk-selection of women for 
postpartum intervention trials aimed at reducing the risk for, or the severity of, these later-life 
diseases. 
The demonstrated role of PlGF in enhancing blood flow and contractile function of ischemic 
myocardium underlines its role in vascular homeostasis, and provides room for a hypothesis of an 
indirect interplay between preeclampsia and CVD (116).  If PlGF improves myocardial function, 
and its levels decrease during preeclampisa, it is possible that the low PlGF state of preeclampsia 
can contribute as a factor increasing the risk of CVD through long-term effects on cardiac function. 
sEng, released in excess from a dysfunctional placenta, may have negative effects on vascular tone 
(51), possibly also adding to the  factors that may mediate a relation between preeclampsia, CVD 
and DM. A genetical link between CVD and preeclampsia is also under investigation, and recent 
research by our group has demonstrated a G-protein phenotype, which plays a role in blood pressure 
regulation, which also affects the risk for and progression of preeclampsia (117).   
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As for breast cancer, an anti-angiogenic state opposes tumor development (118). We 
propose that a woman’s general angiogenic response disposition, whether in pregnancy or if 
challenged by breast tumor growth, might represent a link between the anti-angiogenic state in 
pregnancy and a later beneficial low tumor growth situation in the same woman.   
At present, longitudinal studies after a preeclamptic pregnancy point in different directions 
regarding long-term angiogenic dysregulation. Some studies show no difference in the 
concentrations of circulating PlGF and sFlt1, measured both one (119) and ten (120) years post-
partum between women with previous preeclampsia and control individuals. The same is seen for 
sEng one year post-partum (119). One study showed that circulating sFlt1 levels are raised 18 
months after preeclampsia (121). We also found higher median circulating sFlt1 in women with 
previous preeclampsia complicated by SGA in our own long-term follow-up study (5-8 years after 
preeclampsia), together with evidence of maternal and child endothelial dysfunction (122). In 
several studies increased arterial stiffness after preeclampsia has been shown (119;123;124).  
As circulating PlGF has opposite patterns in CVD and preeclampsia, with augmented levels 
in the former and very low levels in the latter, there is no intuitive logical link between these two 
syndromes with abnormal PlGF situations. Circulating PlGF is elevated in older persons with a high 
risk of a future CVD event, where circulating PlGF stems from excessive vascular inflammation. In 
contrast, low PlGF in pregnancy (probably mostly due to binding of free PlGF to excessive sFlt1 
secondary to a dysfunctional placenta) appears predictive of preeclampsia and fetal growth 
restriction. At present we do not know whether a dysregulated angiogenic factor situation in 
pregnancy is just a marker of the future health risk for the women, possibly reflecting a common 
genetic risk for preeclampsia and future cardiovascular disease. The other alternative is that 
dysregulated angiogenic factors in pregnancy could also mediate future health problems, for 
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example by directly or indirectly affecting vascular health. The first alternative does not exclude the 
latter. 
An interesting link between CVD and preeclampsia is that both have foam cell deposition in 
arteries, as preeclampsia often is complicated by uteroplacental acute atherosis (10). We are at 
present studying whether there is a link between these vascular inflammatory changes in CVD and 
preeclampsia and are using a decidual vacuum suction method that is optimal for collecting relevant 
uteroplacental tissue to study inflammatory lesions of these uteroplacental arteries (125).  
As women with a history of hypertensive disorders in pregnancy have an increased risk for 
developing future diabetes mellitus (36-38;42) ), a prevention program and follow-up would be 
desirable, but this is not the clinical practice world-wide. GDM is a strong risk factor for future 
diabetes, and women with GDM are today in many countries recommended to undergo postpartum 
DM screening (43). According to the annual report of the Norwegian Medical Birth Register (126), 
more women experience gestational hypertension and preeclampsia than GDM. We therefore 
believe that the group of women who have experienced gestational hypertension or preeclampsia 
are important candidates for DM (127) as well as for CVD follow-up programs, in order to prevent 
or enable early diagnosis and treatment of these diseases.  
Current available tests for the circulating angiogenic factors sFlt1, sEng and PlGF have too 
low sensitivity and specificity to be used singularly as a screening tool for preeclampsia in low-risk 
pregnancies, although the use of PlGF in women with suspected preeclampsia after week 35 is 
promising. No cost-benefit analyses have hitherto been published comparing these biomarkers or 
their combinations, but among the single biomarkers, PlGF seems today to be the better predictor 
for preeclampsia (128).  
Cnossen argues that when it comes to the questions of specificity and sensitivity in 
screening for preeclampsia, high sensitivity is preferable, if one has to choose (129). Preeclampsia 
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is a disease that can result in maternal and fetal death, and low sensitivity is therefore absolutely 
unfavorable. On the other hand, low specificity will lead to unnecessary use of health resources and 
cause unnecessary concern and burden for healthy pregnant women. Future studies must bear in 
mind that the ultimate goal of the research on preeclampsia-related biomarkers is not to predict and 
reduce the incidence of preeclampsia, but to improve maternal and child health, both in the short 
and in the long run. 
Currently, there are few effective primary or secondary prophylaxis options for 
preeclampsia. A limited effect of acetylsalicylic acid is known; and women at elevated risk of 
developing preeclampsia are recommended daily acetylsalicylic acid from around week 12 of 
pregnancy (130;131). Several other clinical intervention studies have attempted to prevent 
preeclampsia development by testing effects of vitamins, fish oil, diets, calcium and exercise (132-
138), but they have not been successful in reducing the preeclampsia-risk across populations. A 
good predictive biomarker could potentially be useful to select and monitor high-risk patients for 
future prophylactic trials. Maternal angiogenic factors measured early in pregnancy or at diagnosis 
of preeclampsia could have a potential use in this setting. In developing countries, with limited 
blood assessment accessibility, a urine dip-stix test would be preferable, and probably also cost-
effective compared to blood testing. Urine based biomarkers for PE have, however,  up to the 
present time not been proven to be of use (16). 
Further validation of the clinical use of placenta-associated biomarkers, such as the 
angiogenic factors, is necessary. Cost-benefit analyses are needed before routine clinical 
implementation of maternal angiogenic factors. Also, longitudinal studies across pregnancy cohorts 
are needed to assess whether dysregulated maternal angiogenic factors measured in pregnancy can  
be securely associated with future risk of cardiovascular disease, diabetes mellitus and possibly 
breast cancer (53). The future hope is that a combination of biomarkers reflecting both the placental 
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(such as PlGF) and maternal pathophysiology of preeclampsia (such as preexisting risk factors in 
the mother), as well as dysregulated cardiovascular-derived circulating biomarkers (139) may 
improve diagnostic accuracy and clinical management of preeclampsia and link to future health 
risks (1). It is time to improve the subgrouping of preeclampsia, perhaps using angiogenic placenta-
derived biomarkers such as PlGF (14). Despite great advances both clinically and research-wise in 
industrialized countries over the last decades, our pathophysiological understanding of preeclampsia 
is still relatively limited. This limitation may have consequences for the low predictive value of 
angiogenic factors for late-onset preeclampsia. In late-onset preeclampsia dysregulated placentation 
is not viewed as an essential pathophysiological event. That could possibly explain why this sub-
group of preeclamptic women is less well predicted by dysregulated circulating placenta-derived 
biomarkers, and  is in line with our  new hypothesis that circulating angiogenic biomarkers in 
pregnancy are better considered as markers of a syncytiotrophoblast stress-response rather than of 
preeclampsia or fetal growth restriction (140). 
If we can document a relation (even if there would be no mechanistic associations) between 
dysregulated angiogenic factors in pregnancy (most likely due to placental dysfunction) and an 
augmented risk for future CVD, targeted intervention studies for women at highest risk could be 
undertaken in order to prevent, postpone or reduce the severity of CVD. The several decades (22) 
that may lie between a pregnancy with a dysfunctional placenta and the first clinical signs of CVD 
represent a large “window of opportunity” for intervention programs in women at highest risk, with 
potentially reduced health cost for the woman, her family and society and for enhancing quality of 
life. 
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